ATE314066T1 - Verwendung von buprenorphin zur therapie der harninkontinenz - Google Patents

Verwendung von buprenorphin zur therapie der harninkontinenz

Info

Publication number
ATE314066T1
ATE314066T1 AT02708327T AT02708327T ATE314066T1 AT E314066 T1 ATE314066 T1 AT E314066T1 AT 02708327 T AT02708327 T AT 02708327T AT 02708327 T AT02708327 T AT 02708327T AT E314066 T1 ATE314066 T1 AT E314066T1
Authority
AT
Austria
Prior art keywords
buprenorphine
urinary incontinence
treatment
increased
urinary
Prior art date
Application number
AT02708327T
Other languages
German (de)
English (en)
Inventor
Johannes Bartholomaeus
Thomas Christoph
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2001107828 external-priority patent/DE10107828A1/de
Priority claimed from DE20115429U external-priority patent/DE20115429U1/de
Priority claimed from DE2001162704 external-priority patent/DE10162704A1/de
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Application granted granted Critical
Publication of ATE314066T1 publication Critical patent/ATE314066T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061Polyacrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/28Compounds containing heavy metals
    • A61K31/305Mercury compounds
    • A61K31/31Mercury compounds containing nitrogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02708327T 2001-02-16 2002-02-18 Verwendung von buprenorphin zur therapie der harninkontinenz ATE314066T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE2001107828 DE10107828A1 (de) 2001-02-16 2001-02-16 Verwendung von Buprenorphin zur Therapie der Harninkontinenz
DE20115429U DE20115429U1 (de) 2001-09-18 2001-09-18 Opioide in der Harninkontinenz
DE2001162704 DE10162704A1 (de) 2001-12-19 2001-12-19 Verwendung von Buprenorphin zur Therapie der Harninkontinenz
PCT/EP2002/001699 WO2002066031A1 (de) 2001-02-16 2002-02-18 Verwendung von buprenorphin zur therapie der harninkontinenz

Publications (1)

Publication Number Publication Date
ATE314066T1 true ATE314066T1 (de) 2006-01-15

Family

ID=27214302

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02708327T ATE314066T1 (de) 2001-02-16 2002-02-18 Verwendung von buprenorphin zur therapie der harninkontinenz

Country Status (14)

Country Link
US (1) US20040102468A1 (https=)
EP (1) EP1368023B1 (https=)
JP (1) JP4908726B2 (https=)
AT (1) ATE314066T1 (https=)
AU (1) AU2002242705B2 (https=)
CA (1) CA2438339C (https=)
DE (1) DE50205438D1 (https=)
DK (1) DK1368023T3 (https=)
ES (1) ES2255607T3 (https=)
HU (1) HU229354B1 (https=)
MX (1) MXPA03006742A (https=)
NZ (1) NZ528064A (https=)
PL (1) PL204638B1 (https=)
WO (1) WO2002066031A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1323421A1 (en) * 2001-12-20 2003-07-02 Grünenthal GmbH Use of buprenorphine for the manufacture of a transdermal delivery device for the treatment of urinary incontinence, especially urge incontinence
US8260389B2 (en) * 2003-10-15 2012-09-04 Hegln (Dalian) Pharmaceuticals, Inc. Bladder function monitoring methods, apparatuses, media and signals
EP1682002A4 (en) 2003-10-15 2010-03-31 Univ British Columbia METHOD AND DEVICE FOR URODYNAMIC ANALYSIS
JP6370802B2 (ja) * 2012-12-28 2018-08-08 テイコク ファーマ ユーエスエー インコーポレーテッド 持続性ブプレノルフィン経皮送達組成物およびそれの使用方法
EP3067357A1 (en) 2015-03-11 2016-09-14 Siegfried AG Method of manufacturing stereoisomers of buprenorphine and analogues thereof
CN107320770A (zh) * 2017-07-12 2017-11-07 江苏西宏生物医药有限公司 一种注射植入剂
EP4613751A1 (en) 2024-03-07 2025-09-10 Siegfried AG Method of making chemical compounds useful for the synthesis of buprenorphine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486362A (en) * 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
DE4446600A1 (de) * 1994-12-24 1996-06-27 Lohmann Therapie Syst Lts Transdermale Resorption von Wirkstoffen aus unterkühlten Schmelzen
DE69631525T2 (de) * 1995-03-03 2004-12-16 Endo Pharmaceuticals Inc. Verwendung von dextromethorphan oder dextrorphan zur behandlung der harninkontinenz
JPH1036265A (ja) * 1996-07-19 1998-02-10 Nitto Denko Corp ブプレノルフィン経皮吸収製剤
US5968547A (en) * 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US5900420A (en) * 1997-06-19 1999-05-04 Cole; William L. Method for treating chronic fatigue syndrome and fibromyalgia with buprenorphine
IT1302682B1 (it) * 1998-10-16 2000-09-29 Formenti Farmaceutici Spa Composizioni farmaceutiche orali contenenti buprenorfina

Also Published As

Publication number Publication date
JP2004525900A (ja) 2004-08-26
EP1368023A1 (de) 2003-12-10
HU229354B1 (en) 2013-11-28
MXPA03006742A (es) 2003-10-24
CA2438339C (en) 2010-12-14
DE50205438D1 (de) 2006-02-02
DK1368023T3 (da) 2006-02-13
NZ528064A (en) 2006-03-31
PL204638B1 (pl) 2010-01-29
US20040102468A1 (en) 2004-05-27
WO2002066031A1 (de) 2002-08-29
HUP0302984A3 (en) 2006-02-28
CA2438339A1 (en) 2002-08-29
JP4908726B2 (ja) 2012-04-04
EP1368023B1 (de) 2005-12-28
AU2002242705B2 (en) 2006-08-24
PL367401A1 (en) 2005-02-21
ES2255607T3 (es) 2006-07-01
HUP0302984A2 (hu) 2003-12-29

Similar Documents

Publication Publication Date Title
DE60023043T2 (de) (S,S)-Reboxetin zur Behandlung von Inkontinenz
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
DE60136826D1 (de) Verwendung von asiatsäure oder asiaticosid zur behandlung von krebs
MXPA03011515A (es) Nuevas composiciones de medicamentos sobre la base de agentes anticolinergicos, corticoesteroides y agentes betamimeticos.
DE60219793D1 (de) Methode zur behandlung von zytokinvermittelten erkrankungen
ATE380548T1 (de) Verwendung von p53 inhibitoren zur behandlung von nebenerscheinungen bei der krebstherapie
WO2003080582A3 (de) Fredericamycin-derivate
TW200528117A (en) Methods and reagents for the treatment of proliferative diseases
ATE555803T1 (de) Verwendung von osteopontin zur behandlung und/oder vorbeugung von neurologischen erkrankungen
ATE368455T1 (de) Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
BR0312446A (pt) 2-heteroaril carboxamidas
ATE402694T1 (de) Verwendung von 1-phenyl-3-dimethylamino-propan- verbindungen zur therapie der harninkontinenz
WO2004073615A8 (en) Deazaflavin compounds and methods of use thereof
ATE314066T1 (de) Verwendung von buprenorphin zur therapie der harninkontinenz
ATE252383T1 (de) Verwendung von 2-methyl-thiazolidin-2,4- dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
TR200200278T2 (tr) Kalsilitik bileşimler
DE50313329D1 (de) 1-phenyl-2-dimethylaminomethylcyclohexanverbindungen zur therapie von depressiven symptomatiken, schmerz und inkontinenz
DK1596879T3 (da) Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis
DE60034110D1 (de) Verwendung von 4-aminopyridin zur behandlung von peripheren neuropathien
ATE315387T1 (de) Verwendung von substituierten 6- dimethylaminomethyl-1-phenyl- cyclohexanverbindungen zur therapie der harninkontinenz
DE60335980D1 (de) Verfahren zur herstellung von synthetischen derivaten von dibenzylbutyrolacton-lignanen mit antichagas eigenschaften
ATE423780T1 (de) Makrozyclen zur behandlung von krebserkrankungen
ATE341323T1 (de) Verwendung von darifenacin zur behandlung des harndrangs
AU2001276323A1 (en) Use of n-oleoylethanolamine for treating psoriasis
ATE350034T1 (de) Verwendung von epothilone zur behandlung hyperparathyreoidismus